Analysis of siRNA Drugs at Denaturing UPLC Conditions Using MaxPeak Premier Column Technology

Library Number:
Part Number:
Irene Suarez Marina, Willy Verluyten, Evelien Dejaegere, Leslie Napoletano, J-P Boon, Mario Hellings, Martin Gilar
Janssen Pharmaceutical Companies of Johnson & Johnson, Waters Corporation
Content Type:
Application Notes
Content Subtype:
Application Notes
Related Products:

This application note demonstrates the utility of ACQUITY Premier Peptide BEH C18, 300 Å Column for analysis of small interfering RNA (siRNA) therapeutic candidate compound. 

Title Format File Size
Download PDF PDF 718.91kB